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was barred by large vessels between the gastric
and cystic walls. CT guided aspiration was
performed via an 8.4 Fr pigtail catheter. The
contrast medium showed that the cyst was not
communicating. It was refilled with povidone
iodate and emptied after five minutes. The
catheter was removed after one week. CT at six
months showed complete regression (fig 1)
and the symptoms have not returned.
This is the first description of lavage of a
mucinous pancreatic cystadenoma with povi-
done iodate. This substance damages the
epithelia and is effective in the treatment of
renal cysts,3 4 fistulae, lymphoceles after renal
transplantation,5 6 and hydatid cysts.7 It could
prove a valid alternative to ethanol8 when
surgery is impracticable.
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markedly with patient age
The microsatellite instability phenotype
(MSI+) is observed in approximately 25% of
colon cancers and 2% of rectal cancers. MSI+
is a hallmark of almost all hereditary non-
polyposis colorectal cancers (HNPCC) where
it is associated with germline mutations in
one of the DNA mismatch repair genes.1
However, the large majority of MSI+ cancers
occur as sporadic cases that arise following
methylation induced silencing of the hMLH1
gene promoter. Sporadic MSI+ tumours are
believed to originate in serrated polyps and
display frequent and concurrent methylation
of gene promoter regions but low frequencies
of KRAS and TP53 mutations.2 In contrast,
HNPCC associated MSI+ tumours originate in
conventional adenomas and show frequent
APC and KRAS mutations but infrequent
methylation. Another striking difference is
that BRAF mutations occur in most sporadic
MSI+ tumours but have never been observed
in HNPCC-MSI+ tumours.3 4 While there are
clearly major differences between sporadic
and familial MSI+ tumours, we investigated
here whether patient age was also an
important factor that could influence MSI+
tumour phenotype.
The frequency of the BRAF mutation was
evaluated in MSI+ tumours from a consecu-
tive series of colorectal cancer (CRC) patients
aged ,60 years (n = 828) who were enrolled
in a population based screening programme
for HNPCC in the state of Western Australia.
A total of 66 MSI+ cases (8%) were identified
using the BAT26 mononucleotide marker, of
which only five (7.6%) contained a BRAF
mutation. Family cancer history and germ-
line mutation status for all 66 MSI+ cases
have yet to be determined but preliminary
data suggest that less than one third will be
HNPCC. For comparison, BRAF mutations
were also investigated in non-selected MSI+
patients aged>60 years. Of 45 MSI+ cases, 27
(60%) showed a BRAF mutation, with a
highly significant difference in frequency
between young and old MSI+ patients
(p,161025). These results are almost iden-
tical to those of another recent population
based study which reported a BRAF mutation
frequency of 7% in MSI+ tumours from
patients aged ,55 years and 61% in those
aged 55–79 years (p = 0.0002).5
The frequency of methylation in five gene
promoter regions (hMLH1, p16, p14, TIMP3,
and MINT2) was also compared between
MSI+ tumours from young and old patients
derived from a non-selected CRC series. In six
MSI+ tumours from patients aged ,60 years,
only 2/30 (7%) of the CpG islands investi-
gated by MethyLight assay were methylated.
A much higher frequency (61/100, 61%) was
observed in 20 MSI+ tumours from patients
aged >60 years (p,161025). These results
concur with an earlier study showing that
patients with hMLH1 methylated MSI+
tumours were, on average, 18 years older
than those without hMLH1 methylation.6
The above results on the frequencies of
BRAF mutation and promoter methylation
demonstrate the existence of striking age
related differences in MSI+ phenotype. In
view of the very low incidence of HNPCC
(0.5–1.5% of all CRC), these differences are
likely to involve a much greater proportion of
MSI+ tumours than simply the rare cases
with germline mutations in mismatch repair
genes. We estimate that 30–40% of MSI+
tumours in population based CRC cohorts
belong to a subgroup characterised by the
absence of both BRAF mutation and promoter
methylation.
The clinical significance of these findings
relates to the potential prognostic and pre-
dictive values of MSI+. Current disagreement
in the literature concerning the predictive
value of MSI+ for response to 5-fluorouracil
(5FU) chemotherapy7–10 could be due to the
relative proportion of HNPCC and younger
MSI+ cases included within these studies.
BRAF mutation and gene promoter methyla-
tion, or other factors closely associated with
these features, may be strong determinants of
the response to 5FU. We therefore recom-
mend consideration of this issue in future
studies aimed at evaluating the predictive
significance of MSI+ in colon cancer.
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Figure 1 (A) Computed tomography scan showing an 8 cm pancreatic body cyst. (B) Cyst
regression at six months after lavage with povidone iodine.
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mutation in the SPINK1 gene
causes exon 3 skipping and loss
of the trypsin binding site
Previous studies have shown an association
between chronic pancreatitis (CP) and muta-
tions, especially the N34S mutation, in the
serine protease inhibitor Kazal type 1
(SPINK1) gene.1 2 The human SPINK1 gene
is approximately 7.5 kb long and consists of
four exons.3 The gene product consists of 79
amino acids, including a 23 amino acid signal
peptide. In exon 3, SPINK1 possesses a
reactive site that serves as a specific target
substrate for trypsin.4 It has been suggested
that SPINK1 mutations might result in altered
interaction between SPINK1 and trypsin,
thus affecting the protease/antiprotease bal-
ance within the pancreas.1 2 But the under-
lying molecular mechanisms remain unclear.
Splicing defects are estimated to account for
approximately 10–15% of disease causing
mutations in humans.5 Changes in the spli-
cing patterns and in levels of normal tran-
scripts lead to phenotypic differences. The
prevalence of splicing mutations in the
SPINK1 gene is unknown. Most reported
mutations have only been described at the
DNA level and have not been studied at the
mRNA level, mainly due to unavailability of
SPINK1 mRNA from patients.
We have recently shown that the
[2215G.A; IVS3+2T.C] mutation is asso-
ciated with familial and idiopathic CP in
Japan.6 7 Because the IVS3+2T.C mutation
affects the consensus splicing donor site,8 we
hypothesised that this mutation leads to
alternative splicing, resulting in decreased
SPINK1 function. To overcome the difficul-
ties in obtaining human pancreas samples,
SPINK1 mRNA was harvested from the
stomach, where SPINK1 is also abundantly
expressed,9 of (1) a 70 year old male A with
alcoholic CP carrying the homozygous
[2215G.A; IVS3+2T.C] mutation, (2) his
40 year old daughter B, a heterozygote who
had no abdominal complaints to date, and
(3) a 54 year old female C with idiopathic CP,
also heterozygous for the [2215G.A;
IVS3+2T.C] mutation. Total RNA was iso-
lated from biopsy specimen of the stomach.
The entire coding region of the SPINK1 gene
was amplified by reverse transcription-poly-
merase chain reaction (PCR) and sequenced.
Electrophoresis of the reverse transcription
PCR products from subjects carrying the
[2215G.A; IVS3+2T.C] mutation revealed
two bands: a fragment corresponding to a
normal (‘‘F1’’) and a truncated (‘‘F2’’) band
(fig 1). Sequencing of the truncated fragment
revealed complete deletion of exon 3. This
mutated protein was predicted to consist of
63 amino acids: deletion of amino acid
sequence from residues 30–64 and shifting
of the reading frame at amino acid 65.
To our knowledge, this is the first study
showing the splicing problem in the SPINK1
gene at the mRNA level. Northern blot
analysis revealed that the size of the SPINK1
transcript was identical both in the pancreas
and stomach,9 suggesting that exon 3 skip-
ping is also likely to occur in the pancreas. It
is logical to assume that skipping of exon 3
would result in functional loss of SPINK1,
thus affecting the protease/antiprotease bal-
ance within the pancreas. Of note, the
daughter of patient A carrying the hetero-
zygous [2215G.A; IVS3+2T.C] mutation
has not yet developed CP. Because this
mutation has not been found in healthy
controls,7 it is of interest to see whether she
will develop CP in the future. Recently, Le
Marechal and colleagues10 reported the
IVS2+1G.A mutation in a CP patient carry-
ing the P55S mutation in France. The
IVS2+1G.A mutation affects the consensus
splicing donor site of intron 2, implying a role
of another splicing variation. Further studies
using larger numbers of patients and differ-
ent types of mutations will establish the role
of splicing mutations in SPINK1 related CP.
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Neoadjuvant chemoradiation
treatment impairs accuracy of
MRI staging in rectal carcinoma
Neoadjuvant chemoradiotherapy (nCRT) is
considered one of the treatment modalities of
advanced rectal cancer (pT3/T4 or pN+) with
the intention of downsizing and downstaging
the tumour. Tumour restaging may be useful
for planning the operation but tissue altera-
tion after nCRT may disturb the accuracy of
the imaging procedures.
Between July 2004 and August 2005, we
analysed 28 consecutive patients (18 males,
10 females, ,63 years) with adenocarcinoma
of the middle and distal third of the rectum.
High spatial resolution magnet resonance
imaging (MRI) with intraluminary contrast
and endorectal ultrasonography (EUS)
(Olympus EU-M30S, 12 MHz) were per-
formed before and after nCRT as part of their
Figure 1 [2215G.A; IVS3+2] mutation
produced a truncated transcript. Total RNA was
isolated from the biopsy specimen of the
stomach, and the entire coding region of the
serine protease inhibitor Kazal type 1 (SPINK1)
gene was amplified by reverse transcription
polymerase chain reaction, followed by 2 %
agarose gel electrophoresis. Sm, size marker
(100 base pair ladders), WT, healthy control.
Patient A with alcoholic chronic pancreatitis
(CP) was homozygous for the [2215G.A;
IVS3+2T.C] mutation. His daughter B and
patient C with idiopathic CP were
heterozygous. In subjects carrying the
[2215G.A; IVS3+2T.C] mutation, two bands
were observed: a fragment corresponding to a
normal (‘‘F1’’) and a truncated (‘‘F2’’) band.
*K Kume and A Masamune contributed equally to this
work.
Conflict of interest: None declared
1214 PostScript
www.gutjnl.com
 on 1 September 2008 gut.bmj.comDownloaded from 
